Every medicine authorised for the Irish market — 10,165 products with active substances, licence holders, dosage forms and prescription status.
| Medicine | Active substance | Licence holder | Status |
|---|---|---|---|
| IMBRUVICA 420 mg film-coated tablets EU/1/14/945/005 |
Ibrutinib | Janssen-Cilag International NV | — |
| IMBRUVICA 560 mg film-coated tablets EU/1/14/945/006 |
Ibrutinib | Janssen-Cilag International NV | — |
| IMCIVREE 10 mg/ml solution for injection EU/1/21/1564/001 |
Setmelanotide | Rhythm Pharmaceuticals Netherlands B.V | — |
| IMFINZI 50 mg/ml concentrate for solution for infusion. EU/1/18/1322/001-002 |
Durvalumab | AstraZeneca AB | — |
| Imipenem/Cilastatin 250 mg/250 mg powder for solution for infusion PA2059/074/001 |
Imipenem, Cilastatin | Fresenius Kabi Deutschland GmbH | Not marketed |
| Imipenem/Cilastatin 500 mg/500 mg powder for solution for infusion PA2059/074/002 |
Imipenem, Cilastatin | Fresenius Kabi Deutschland GmbH | Marketed |
| IMJUDO 20 mg/ml concentrate for solution for infusion EU/1/22/1713/001-002 |
Tremelimumab | AstraZeneca AB | — |
| Imlygic 10e6 plaque forming units (PFU)/mL solution for injection EU/1/15/1064/001 |
Talimogene laherparepvec | Amgen Europe B.V. | — |
| Imlygic 10e8 plaque forming units (PFU)/mL solution for injection EU/1/15/1064/002 |
Talimogene laherparepvec | Amgen Europe B.V. | — |
| Imnovid 1 mg hard capsules EU/1/13/850/001 |
Pomalidomide | Bristol-Myers Squibb Pharma EEIG | — |
| Imnovid 2 mg hard capsules EU/1/13/850/002 |
Pomalidomide | Bristol-Myers Squibb Pharma EEIG | — |
| Imnovid 3 mg hard capsules EU/1/13/850/003 |
Pomalidomide | Bristol-Myers Squibb Pharma EEIG | — |
| Imnovid 4 mg hard capsules EU/1/13/850/004 |
Pomalidomide | Bristol-Myers Squibb Pharma EEIG | — |
| Imraldi 40 mg solution for injection in pre-filled pen EU/1/17/1216/005-008 |
Adalimumab | Samsung Bioepis NL B.V. | — |
| Imraldi 40 mg solution for injection in pre-filled syringe EU/1/17/1216/001-004 |
Adalimumab | Samsung Bioepis NL B.V. | — |
| Imraldi 40 mg/0.8 ml solution for injection EU/1/17/1216/009 |
Adalimumab | Samsung Bioepis NL B.V. | — |
| Imuldosa 130 mg Concentrate for solution for infusion EU/1/24/1872/003 |
Ustekinumab | Accord Healthcare S.L.U. | — |
| Imuldosa 45 mg Solution for injection EU/1/24/1872/001 |
Ustekinumab | Accord Healthcare S.L.U. | — |
| Imuldosa 90 mg Solution for injection EU/1/24/1872/002 |
Ustekinumab | Accord Healthcare S.L.U. | — |
| IMVANEX suspension for injection EU/1/13/855/001 |
Mva-bn virus | Bavarian Nordic A/S | — |
| Inaqovi 35 mg/100 mg film-coated tablets EU/1/23/1756/001 |
Decitabine, Cedazuridine | Otsuka Pharmaceutical Netherlands B.V. | — |
| Inbrija 33 mg inhalation powder, hard capsules EU/1/19/1390/001-002 |
Levodopa | Merz Pharmaceuticals GmbH | — |
| Incellipan suspension for injection in pre-filled syringe Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures). EU/1/24/1807/001 |
Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen | Seqirus Netherlands B.V. | — |
| Increlex 10 mg/ml solution for injection EU/1/07/402/001 |
Mecasermin | Esteve Pharmaceuticals S.A. | — |
| Incresync 12.5 mg/30 mg film-coated tablets EU/1/13/842/01-09 |
Alogliptin (as benzoate), Pioglitazone (as hydrochloride) | Takeda Pharma A/S | — |
| Incresync 12.5 mg/45 mg film-coated tablets EU/1/13/842/010-018 |
Alogliptin (as benzoate), Pioglitazone (as hydrochloride) | Takeda Pharma A/S | — |
| Incresync 25 mg/30 mg film-coated tablets EU/1/13/842/019-027 |
Pioglitazone (as hydrochloride), Alogliptin (as benzoate) | Takeda Pharma A/S | — |
| Incresync 25 mg/45 mg film-coated tablets EU/1/13/842/028-036 |
Pioglitazone (as hydrochloride), Alogliptin (as benzoate) | Takeda Pharma A/S | — |
| Incruse Ellipta 55 micrograms inhalation powder, pre-dispensed EU/1/14/922/001-003 |
Umeclidinium bromide | GlaxoSmithKline Trading Services Limited | — |
| Indium (In111) Chloride 370MBq/ml radiopharmaceutical precursor PA0690/008/001 |
Indium (111 in) | Curium Netherlands B.V. | Marketed |
| InductOs 1.5 mg/ml powder, solvent and matrix for implantation matrix EU/1/02/226/001 |
Dibotermin alfa | Medtronic BioPharma B.V. | — |
| Infanrix hexa EU/1/00/152/001 |
Haemophilus influenzae, Pertussis toxoid, Tetanus toxoid, Polysaccharide-k, Diphtheria toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/002 |
Haemophilus influenzae, Hbs ag, Tetanus toxoid, Pertussis toxoid, Filamentous haemagglutinin | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/003 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/004 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/005 |
Pertactin, Pertussis toxoid, Hbs ag, Diphtheria toxoid, Filamentous haemagglutinin | GlaxoSmithKline Biologicals | — |
| Infanrix hexa EU/1/00/152/006 |
Filamentous haemagglutinin, Polysaccharide-k, Diphtheria toxoid, Haemophilus influenzae, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | Marketed |
| Infanrix hexa EU/1/00/152/007 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/008 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/009 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/010 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/011 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/012 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals | — |
| Infanrix hexa EU/1/00/152/013 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/014 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/015 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Infanrix hexa EU/1/00/152/016 |
Haemophilus influenzae, Pertactin, Diphtheria toxoid, Polysaccharide-k, Tetanus toxoid | GlaxoSmithKline Biologicals S.A. | — |
| Inflectra 100 mg powder for concentrate for solution for infusion EU/1/13/854/001-005 |
Ct-p13 (infliximab) | Pfizer Europe MA EEIG | — |
| Infutraze concentrate for solution for infusion PA2059/083/001 |
Copper chloride dihydrate, Manganese chloride tetrahydrate, Potassium iodide, Sodium selenite anhydrous, Zinc chloride | Fresenius Kabi Deutschland GmbH | Not marketed |
| Inhixa 10,000 IU (100 mg)/1 mL solution for injection in pre-filled syringe EU/1/16/1132/009-010 |
Enoxaparin sodium | Techdow Pharma Netherlands B.V | — |
Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 16 August 2026).
Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.